Why the study?
Direct oral anticoagulants are not approved for mechanical valves and may lead to catastrophic consequences when replacing vitamin K antagonists.
The use of direct oral anticoagulants like rivaroxaban in patients with mechanical heart valves can lead to catastrophic consequences such as valve thrombosis.
Caution against rivaroxaban in mechanical mitral valves; case report leaves open need for dedicated trials.
Direct oral anticoagulants are not approved for use in patients with mechanical valves. When used to replace vitamin K antagonists, they may cause catastrophic consequences. The authors describe the case of a patient who, after discontinuation of warfarin and introduction of rivaroxaban, developed thrombosis of his mechanical mitral prosthesis.
No takes yet. Share an insight, caveat, or question.
Braga et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: